Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329

Benzinga · 1d ago
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.